{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:02:35Z","timestamp":1784768555535,"version":"3.55.0"},"reference-count":47,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Toxicology and Applied Pharmacology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.taap.2026.117835","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:02:38Z","timestamp":1777590158000},"page":"117835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Non-clinical pharmacology, pharmacokinetics, and safety evaluation of TAX2, a first-in-class peptide targeting the TSP-1\/CD47 matricellular axis"],"prefix":"10.1016","volume":"512","author":[{"given":"Aub\u00e9ri","family":"Henry","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Etiennot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariem","family":"Ghoula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia","family":"Poli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Dedieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albin","family":"Jeanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Moniot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.taap.2026.117835_bb0005","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/CMR.0000000000000629","article-title":"Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade","volume":"30","author":"Anderson","year":"2020","journal-title":"Melanoma Res."},{"key":"10.1016\/j.taap.2026.117835_bb0010","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178943","article-title":"Differential stability of therapeutic peptides with different proteolytic cleavage sites in blood, plasma and serum","volume":"12","author":"Bo\u00f6ttger","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.taap.2026.117835_bb0015","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41573-024-00942-3","article-title":"The state of the art in secondary pharmacology and its impact on the safety of new medicines","volume":"23","author":"Brennan","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.taap.2026.117835_bb0020","doi-asserted-by":"crossref","first-page":"7054","DOI":"10.1200\/JCO.2022.40.16_suppl.7054","article-title":"Impact of magrolimab treatment in combination with azacitidine on red blood cells in patients with higher-risk myelodysplastic syndrome (HR-MDS)","volume":"40","author":"Chen","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2026.117835_bb0025","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1006\/abio.1997.2145","article-title":"Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450","volume":"248","author":"Crespi","year":"1997","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.taap.2026.117835_bb0030","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-08480-y","article-title":"Deciphering the complex role of thrombospondin-1 in glioblastoma development","volume":"10","author":"Daubon","year":"2019","journal-title":"Nat. Commun."},{"key":"10.1016\/j.taap.2026.117835_bb0035","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1177\/0192623315625859","article-title":"Recommendations from the INHAND apoptosis\/necrosis working group","volume":"44","author":"Elmore","year":"2016","journal-title":"Toxicol. Pathol."},{"issue":"1","key":"10.1016\/j.taap.2026.117835_bb9043","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.abb.2008.07.015","article-title":"Human thrombospondin's (TSP-1) C-terminal domain opens to interact with the CD-47 receptor: a molecular modeling study","volume":"478","author":"Floquet","year":"2008","journal-title":"Arch Biochem Biophys"},{"key":"10.1016\/j.taap.2026.117835_bb0040","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-019-1406-7","article-title":"Regulation of senescence escape by TSP1 and CD47 following chemotherapy treatment","volume":"10","author":"Guillon","year":"2019","journal-title":"Cell Death Dis."},{"issue":"2","key":"10.1016\/j.taap.2026.117835_bb9044","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.molcel.2008.05.026","article-title":"Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47","volume":"31","author":"Hatherley","year":"2008","journal-title":"Mol Cell"},{"issue":"14","key":"10.1016\/j.taap.2026.117835_bb9045","doi-asserted-by":"crossref","first-page":"10024","DOI":"10.1074\/jbc.M114.550558","article-title":"Polymorphisms in the human inhibitory signal-regulatory protein \u03b1 do not affect binding to its ligand CD47","volume":"289","author":"Hatherley","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.taap.2026.117835_bb0045","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-021-00544-0","article-title":"Extracellular matrix and its therapeutic potential for cancer treatment","author":"Huang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.taap.2026.117835_bb0050","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2015.00252","article-title":"Original insights on thrombospondin-1-related antireceptor strategies in cancer","author":"Jeanne","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.taap.2026.117835_bb0055","doi-asserted-by":"crossref","first-page":"17981","DOI":"10.18632\/oncotarget.4025","article-title":"Identification of TAX2 peptide as a new unpredicted anti-cancer agent","volume":"6","author":"Jeanne","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.taap.2026.117835_bb0060","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s10585-016-9803-0","article-title":"Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide","volume":"33","author":"Jeanne","year":"2016","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.taap.2026.117835_bb0065","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/pr.2016.242","article-title":"Thrombospondin-targeting TAX2 peptide impairs tumor growth in preclinical mouse models of childhood neuroblastoma","volume":"81","author":"Jeanne","year":"2017","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.taap.2026.117835_bb0070","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-07043-9","article-title":"Lumican delays melanoma growth in mice and drives tumor molecular assembly as well as response to matrix-targeted TAX2 therapeutic peptide","volume":"7","author":"Jeanne","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.taap.2026.117835_bb0075","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/ATVBAHA.120.314571","article-title":"Towards the therapeutic use of thrombospondin 1\/CD47 targeting TAX2 peptide as an antithrombotic agent","volume":"41","author":"Jeanne","year":"2021","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.taap.2026.117835_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13195019","article-title":"Targeting ovarian carcinoma with TSP-1:CD47 antagonist TAX2 activates anti-tumor immunity","volume":"13","author":"Jeanne","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.taap.2026.117835_bb0085","article-title":"Targeting the CD47\/SIRP\u03b1 pathway in malignancies: recent progress, difficulties and future perspectives","author":"Jiang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.taap.2026.117835_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22084062","article-title":"Thrombospondin-1 cd47 signalling: from mechanisms to medicine","author":"Kale","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2026.117835_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcdb.2023.05.008","article-title":"Emerging functions of thrombospondin-1 in immunity","author":"Kaur","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.taap.2026.117835_bb0100","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22094570","article-title":"Functions of thrombospondin-1 in the tumor microenvironment","author":"Kaur","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.taap.2026.117835_bb0105","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-010565","article-title":"First-in-human phase i trial of the bispecific CD47 inhibitor and CD40 agonist fc-fusion protein, SL-172154 in patients with platinum-resistant ovarian cancer","volume":"13","author":"Lakhani","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.taap.2026.117835_bb0110","article-title":"Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential","volume":"10","author":"Liu","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.taap.2026.117835_bb0115","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/cas.15237","article-title":"Thrombospondin-1 induced programmed death-ligand 1-mediated immunosuppression by activating the STAT3 pathway in osteosarcoma","volume":"113","author":"Liu","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.taap.2026.117835_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.apsb.2025.10.026","article-title":"Progress in peptide and protein therapeutics: challenges and strategies","author":"Liu","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.taap.2026.117835_bb0125","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13164059","article-title":"Thrombospondin-1 silencing improves lymphocyte infiltration in tumors and response to anti-pd-1 in triple-negative breast cancer","volume":"13","author":"Marcheteau","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.taap.2026.117835_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-024-02073-0","article-title":"The CD47\/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research","volume":"23","author":"Moniot","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.taap.2026.117835_bb0135","doi-asserted-by":"crossref","DOI":"10.1007\/s00262-023-03465-9","article-title":"The TSP1-CD47-SIRP\u03b1 interactome: an immune triangle for the checkpoint era","author":"Montero","year":"2023","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.taap.2026.117835_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.semcdb.2023.05.010","article-title":"Thrombospondins in the tumor microenvironment","author":"Petrik","year":"2024","journal-title":"Semin. Cell Dev. Biol."},{"key":"10.1016\/j.taap.2026.117835_bb0145","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3109\/03008207.2015.1045065","article-title":"Expression of thrombospondin-1 by tumor cells in patient-derived ovarian carcinoma xenografts","volume":"56","author":"Pinessi","year":"2015","journal-title":"Connect. Tissue Res."},{"key":"10.1016\/j.taap.2026.117835_bb0150","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/BF03032381","article-title":"Expression of thrombospondin-1 in human pancreatic adenocarcinomas: role in matrix metalloproteinase-9 production","volume":"7","author":"Qian","year":"2001","journal-title":"Pathol. Oncol. Res."},{"key":"10.1016\/j.taap.2026.117835_bb0155","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.22.01794","article-title":"Magrolimab in combination with azacitidine in patients with higher-risk myelodysplastic syndromes: final results of a phase Ib study","volume":"41","author":"Sallman","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.taap.2026.117835_bb0160","series-title":"Journal of Clinical Oncology","first-page":"946","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","author":"Sikic","year":"2019"},{"key":"10.1016\/j.taap.2026.117835_bb0165","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jpba.2014.03.018","article-title":"A cocktail approach for assessing the in vitro activity of human cytochrome P450s: an overview of current methodologies","volume":"101","author":"Spaggiari","year":"2014","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.taap.2026.117835_bb0170","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-004712","article-title":"Targeting the CD47\/thrombospondin-1 signaling axis regulates immune cell bioenergetics in the tumor microenvironment to potentiate antitumor immune response","volume":"10","author":"Stirling","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.taap.2026.117835_bb0175","doi-asserted-by":"crossref","DOI":"10.1186\/s12881-020-01073-3","article-title":"Role of TSP-1 as prognostic marker in various cancers: a systematic review and meta-analysis","author":"Sun","year":"2020","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.taap.2026.117835_bb0180","article-title":"CD47-targeting antibodies as a novel therapeutic strategy in hematologic malignancies","volume":"16","author":"Sun","year":"2021","journal-title":"Leuk. Res. Rep."},{"issue":"1","key":"10.1016\/j.taap.2026.117835_bb0185","first-page":"1","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.taap.2026.117835_bb0190","article-title":"The solid tumor microenvironment and related targeting strategies: a concise review","author":"Wang","year":"2025","journal-title":"Front. Immunol."},{"issue":"12","key":"10.1016\/j.taap.2026.117835_bb0195","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1038\/s41590-025-02321-5","article-title":"Thrombospondin-1\u2013CD47 signaling contributes to the development of T cell exhaustion in cancer","volume":"26","author":"Weng","year":"2025","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.taap.2026.117835_bb0200","doi-asserted-by":"crossref","DOI":"10.3892\/ol.2024.14389","article-title":"Progress in cancer research on the regulator of phagocytosis CD47, which determines the fate of tumor cells (review)","author":"Wu","year":"2024","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.taap.2026.117835_bb0205","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"17","key":"10.1016\/j.taap.2026.117835_bb9046","doi-asserted-by":"crossref","first-page":"5574","DOI":"10.3390\/molecules27175574","article-title":"Crystal Structure of Human CD47 in Complex with Engineered SIRP\u03b1.D1(N80A)","volume":"27","author":"Yu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.taap.2026.117835_bb0210","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current strategies in extending half-lives of therapeutic proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J. Control. Release"},{"key":"10.1016\/j.taap.2026.117835_bb0215","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1208\/s12248-012-9332-y","article-title":"Applications of human pharmacokinetic prediction in first-in-human dose estimation","volume":"14","author":"Zou","year":"2012","journal-title":"AAPS J."}],"container-title":["Toxicology and Applied Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26001316?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0041008X26001316?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:38:56Z","timestamp":1784767136000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0041008X26001316"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":47,"alternative-id":["S0041008X26001316"],"URL":"https:\/\/doi.org\/10.1016\/j.taap.2026.117835","relation":{},"ISSN":["0041-008X"],"issn-type":[{"value":"0041-008X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-clinical pharmacology, pharmacokinetics, and safety evaluation of TAX2, a first-in-class peptide targeting the TSP-1\/CD47 matricellular axis","name":"articletitle","label":"Article Title"},{"value":"Toxicology and Applied Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.taap.2026.117835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117835"}}